Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies (vol 20, pg 589, 2017)

Wei J. C. C.; Baeten D.; Sieper J.; Deodhar A.; Bhosekar V; Martin R.; Porter B.

首页> 外文期刊>International journal of rheumatic diseases >Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies (vol 20, pg 589, 2017)

【24h】

Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies (vol 20, pg 589, 2017)

机译：Secukinumab在亚洲患者中有活性强直性脊柱炎的疗效和安全性：两阶段3研究的52周合并结果（Vol 20，PG 589,2017）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International journal of rheumatic diseases 》 |2017年第7期| 共1页
作者
Wei J. C. C.; Baeten D.; Sieper J.; Deodhar A.; Bhosekar V; Martin R.; Porter B.;
展开▼
作者单位

Novartis Pharmaceut E Hanover NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类全身性疾病 ;
关键词

相似文献

外文文献
中文文献

1. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies (vol 20, pg 589, 2017) [J] . Wei J. C. C., Baeten D., Sieper J., International journal of rheumatic diseases . 2017 ,第7期

机译：Secukinumab在亚洲患者中有活性强直性脊柱炎的疗效和安全性：两阶段3研究的52周合并结果（Vol 20，PG 589,2017）
2. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52‐week pooled results from two phase 3 studies [J] . Wei James C.‐C., Baeten Dominique, Sieper Joachim, International journal of rheumatic diseases . 2017 ,第Suppla1期

机译：Secukinumab在亚洲患者有效的强直性脊柱炎患者的疗效和安全性：52周的合并结果来自两阶段3研究
3. SAFETY AND TOLERABILITY OF SECUKINUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED SAFETY ANALYSIS OF TWO INTERNATIONAL PHASE 3, RANDOMIZED, CONTROLLED TRIALS [J] . Deodhar Atul, Baeten Dominique, Sieper Joachim, Journal of clinical rheumatology . 2016 ,第3期

机译：活动性强直性脊柱炎患者西库单抗的安全性和耐受性：两种国际3期随机对照试验的安全性分析
4. IMANI-1 TC3WP Single Drug HAART -Proof of Concept Study Pilot Study of the Safety and Efficacy of Kaletra (LPV/r) as Single Drug HAART in HIV+ ARV- Naive Patients - Interim Analysis of Subjects Completing Final 48 Week Data [C] . J.C. Gathe Jr., M. Washington, C. Mayberry International AIDS Conference . 2004

机译：Imani-1 TC3WP单药搭载概念研究试验试验研究Kaletra（LPV / R）作为艾滋病毒+ ARV天真患者单药HAART的安全性和有效性 - 临时分析受试者完成最终的48周数据
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Efficacy safety and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized double-blind phase 3 study MEASURE 3 [O] . Karel Pavelka, Alan Kivitz, Eva Dokoupilova, 2017

机译：苏金单抗在活动性强直性脊柱炎患者中的疗效安全性和耐受性：一项随机双盲3期临床研究措施3
7. 174 Secukinumab demonstrates consistent safety over long-term exposure up to three years in patients with active ankylosing spondylitis: pooled analysis of three Phase III trials [O] . Nick Barkham, Atul Deodhar, Xenofon Baraliakos, 2018

机译：174 Secukinumab在活性强直性脊柱炎患者中长期暴露于长期暴露的一致安全性：三期III试验的合并分析

Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies (vol 20, pg 589, 2017)

著录项

相似文献

相关主题

期刊订阅